Results 11 to 20 of about 273 (101)

Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis. [PDF]

Antimicrob Agents Chemother, 2022
Delpazolid, an oxazolidinone, has been studied in non-clinical studies of efficacy and toxicity and Phase 1 clinical studies. Delpazolid has in vitro activity against Gram-positive bacteria, including Mycobacterium tuberculosis .
Kim JS, Kim YH, Lee SH, Kim YH, Kim JW, Kang JY, Kim SK, Kim SJ, Kang YS, Kim TH, Mok J, Byun MK, Park HJ, Joh JS, Park YB, Lim HS, Choi H, Lee SH, Kim H, Yang J, Kim H, Shen X, Alsultan A, Cho I, Geiter L, Shim TS.   +25 more
europepmc   +7 more sources

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB. [PDF]

J Antimicrob Chemother
Abstract Introduction Many drugs for the treatment of TB prolong the QTc interval, which is associated with an increased risk of developing a life-threatening arrhythmia known as torsades de pointes. Sutezolid and delpazolid are novel oxazolidinones with demonstrated bactericidal activity. We aimed to
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N, PanACEA consortium .   +28 more
europepmc   +11 more sources

Development of Delpazolid for the Treatment of Tuberculosis [PDF]

Applied Sciences, 2020
A novel oxazolidinone with cyclic amidrazone, delpazolid (LCB01-0371), was synthesized by LegoChem BioSciences, Inc. (Daejeon, Korea). Delpazolid can improve the minimum bactericidal concentration of Mycobacterium tuberculosis H37Rv and significantly ...
Young Lag Cho, Jichan Jang
doaj   +5 more sources

Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China [PDF]

International Journal of Infectious Diseases, 2021
Background: The natural resistance of rapidly growing mycobacteria (RGM) to multiple antibiotics renders the treatment of the infections caused less successful.
Shu’an Wen, Xiaopan Gao, Weijie Zhao, Fengmin Huo, Guanglu Jiang, Lingling Dong, Liping Zhao, Fen Wang, Xia Yu, Hairong Huang   +9 more
doaj   +3 more sources

Synthesis of Oxazolidinones by a Hypervalent Iodine Mediated Cyclization of N‐Allylcarbamates [PDF]

Advanced Synthesis &Catalysis, Volume 363, Issue 6, Page 1646-1650, March 16, 2021., 2021
Abstract The preparation of oxazolidinones by the hypervalent iodine mediated cyclization of allylcarbamates is described. A versatile range of substrates can be converted into substituted oxazolidinones primed for further transformations. Derivatization of the products at both ends is demonstrated.
Mirdyul Das, Arantxa Rodríguez, Pui Kin Tony Lo, Wesley J. Moran   +3 more
wiley   +4 more sources

In-vitro Activity of Delpazolid and Comparator Agents Against Methicillin-resistant Staphylococcus aureus Involved in Bloodstream Infection. [PDF]

Ann Lab Med, 2023
Park JS, Choi YJ, Kwon K, Choi SJ, Moon SM, Song KH, Kim ES, Park KU, Kim HB.   +8 more
europepmc   +3 more sources

Comparative pharmacokinetics study of two tablet formulations of delpazolid, a novel oxazolidinone class antibiotic. [PDF]

Transl Clin Pharmacol
Delpazolid is an oxazolidinone-class antibiotic under development for treating diseases caused by antimicrobial-resistant gram-positive bacteria. This study compared the pharmacokinetics (PK) and safety of two formulations of delpazolid 400 mg with distinct excipient compositions: Batch No. 3183817R (test drug) and Batch No. 1650006 (reference drug). A
Koh J, Khwarg J, Cho YL, Yu KS, Chung JY.   +4 more
europepmc   +2 more sources

Treatment-shortening regimens for tuberculosis: updates and future priorities. [PDF]

Breathe (Sheff), 2023
In the past 2 years, remarkable advances have been made in shortening tuberculosis (TB) treatment. In particular, four clinical trials (Study 31/A5349, Nix-TB, ZeNix and TB-PRACTECAL) have provided evidence of the efficacy of regimens based on new and ...
Saluzzo F, Adepoju VA, Duarte R, Lange C, Phillips PPJ.   +4 more
europepmc   +4 more sources

Mycobacterium tuberculosis: Pathogenesis and therapeutic targets

MedComm, Volume 4, Issue 5, October 2023., 2023
In this review, we summarize the pathogenesis of TB infection, therapeutic targets, and corresponding modulators, including first‐line medications, current clinical trial drugs and molecules in preclinical assessment. Our review provides valuable insights for future antituberculosis drug development efforts.
Jiaxing Yang, Laiying Zhang, Wenliang Qiao, Youfu Luo   +3 more
wiley   +1 more source

Advances in Key Drug Target Identification and New Drug Development for Tuberculosis

BioMed Research International, Volume 2022, Issue 1, 2022., 2022
Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug‐resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti‐TB drugs to treat drug‐resistant TB and shorten the standard therapy.
Jie Mi, Wenping Gong, Xueqiong Wu, Atef M. Al Attar   +3 more
wiley   +1 more source